Summary of ‘Pharmacotherapy for anxiety disorders in children and adolescents’
✍ Scribed by Evidence-Based Child Health Editorial Office
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 45 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1557-6272
- DOI
- 10.1002/ebch.501
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract This is a commentary on a Cochrane review, published in this issue of EBCH, first published as: Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. __Cochrane Database of Systematic Reviews__ 2009, Issue 3. Art. No.: CD005170. DOI
Pediatric anxiety disorders are prevalent, chronic, and often lead to significant impaired functioning that impacts both short-and long-term outcomes for children and adolescents. Treatment options include pharmacotherapy and psychosocial interventions. This presentation will review treatment advanc
## Abstract ## Background Childhood and adolescent anxiety disorders are relatively common, occurring in between 5‐18% of all children and adolescents. They are associated with significant morbidity and impairment in social and academic functioning, and when persistent, there is a risk of depressi
## Abstract This is a summary of a Cochrane review, published in this issue of EBCH, first published as: Hetrick SE, Merry S, McKenzie J, Sindahl R, Protctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. __Cochrane Database of Systematic Re